Clazakizumab
CSL300_3001
Phase 3 mab terminated
Quick answer
Clazakizumab for Antibody-mediated Rejection is a Phase 3 program (mab) at CSL Behring GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- CSL Behring GmbH
- Indication
- Antibody-mediated Rejection
- Phase
- Phase 3
- Modality
- mab
- Status
- terminated